ZTS:NYSEZoetis Inc. Analysis

Zoetis (ZTS) is trading at $79.57, just above its 20‑day SMA of $79.07 but well below the 50‑day ($97.48) and 200‑day ($122.24) averages, signaling a short‑term pullback within a longer‑term bearish backdrop. The RSI of 37 places the stock in oversold territory, while the MACD histogram is positive, hinting at a potential near‑term bounce toward the $82.98 resistance. Fundamentals remain strong – ROE sits near 68%, operating margins exceed 36%, and the dividend yield of 2.66% is supported by a payout ratio of roughly 33% and robust free cash flow. However, the DCF‑derived fair value of $46.29 is far below the current price, flagging a substantial overvaluation gap despite a P/E of 13× versus an industry average of 25×. Recent headlines add mixed color: analysts label ZTS as an “oversold” buy, Argus Research downgraded the stock to Hold citing rising competition, and a pending class‑action lawsuit introduces legal uncertainty.
Given the blend of solid cash generation, attractive dividend, and defensive animal‑health positioning, the stock’s upside appears limited in the near term while valuation pressures and litigation risk loom. The consensus “Buy” rating from 17 analysts and a median price target of $130 suggest optimism, yet the technical picture and intrinsic valuation point to caution. Investors should weigh the short‑term technical support and dividend appeal against the longer‑term valuation disconnect and pending legal exposure.